Hepatitis B Immunoglobulin-VF (CSL Behring)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHepatitis B Immunoglobulin-VF (CSL Behring)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionImmunostimulantsImmunoglobulin agonists
TargetsImmunoglobulin
Therapy Area/IndicationsHepatitis B
Global Approved IndicationsHepatitis B
Approved Indications in ChinaN/A
Original Approved Country/TerritoryAustralia
Original Approved Date2007/08/01
Country/TerritoryNew ZealandAustralia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCsl Behring Llc
China Registration ClassN/A

Develop Information

Active CompaniesCsl Behring Llc
Inactive CompaniesN/A
Active IndicationsHepatitis B
Inactive IndicationsN/A

Other Information

ATC CodeJ06BB04
Related LinksN/A